Key Highlights

  • Shares trading up 12.54%, adding $1.71 to reach $15.36, near 52-week highs
  • Short interest is around 58% of float, fueling today's short-covering rally
  • Move comes two days after the company priced a $150 million Equity offering at $12.06 per share
  • Rebound follows a volatile stretch that included an FDA rejection of lead melanoma therapy RP1 and subsequent speculation over FDA Leadership changes
  • A newly announced Shareholder class-action investigation adds a layer of legal overhang
  • FDA recently granted Accelerated Approval to Replimune's TUDRIQEV in combination with nivolumab for advanced melanoma

Heavily Shorted Stock Squeezes Higher

Replimune Group (NASDAQ:REPL) shares are rallying sharply today, up 12.54% to $15.36, near 52-week highs, as heavily shorted stock, with short interest around 58% of float, squeezes higher just two days after the company priced a $150 million equity offering at $12.06 per share to shore up its balance sheet. The stock's rebound follows a volatile stretch that included an FDA rejection of lead melanoma therapy RP1 and a subsequent surge tied to speculation over FDA leadership changes.

Replimune Group is a clinical-stage biotechnology company headquartered in Woburn, Massachusetts, focused on developing and commercializing oncolytic immunotherapies to treat cancer. Its proprietary RPx and Immulytic platform engineers selectively replicating herpes simplex virus type 1 constructs to directly kill tumor cells while activating a systemic anti-tumor immune response. The pipeline includes lead candidate RP1, now approved as TUDRIQEV, in late-stage development including a BLA resubmission for advanced melanoma, along with RP2 and RP3, which incorporate additional immune-activating mechanisms.

Legal Overhang Persists Despite Regulatory Milestone

The FDA recently granted accelerated approval to TUDRIQEV, Replimune's intratumoral therapy, in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease has progressed following prior anti-PD-1 therapy, a milestone that followed a favorable FDA Advisory Committee recommendation. Even so, a newly announced shareholder class-action investigation adds a layer of legal overhang as investors bid up the stock on short-covering and renewed risk appetite.

Conclusion

Replimune Group's 12.54% rally today is being driven primarily by a short squeeze in a heavily shorted stock, rather than a fresh fundamental catalyst, following this week's equity raise and a volatile stretch that included both regulatory setbacks and the recent accelerated approval of TUDRIQEV. With short interest still elevated and a shareholder class-action investigation adding legal overhang, the stock's next moves will likely remain highly sensitive to positioning shifts as much as to underlying pipeline news.